gene therapy News
-
CEO and Co-Founder Alla Zamarayeva presents in the Startup Showcase session at the ASGCT Annual
CEO and Co-Founder Alla Zamarayeva PhD presented recently at the Startup Showcase at the ASGCT 25th Annual Conference. The presentation covered how CellFE is leveraging microfluidics to address challenges in cell and gene therapy manufacturing and the business’s long-term vision for growth. The American Society of Cell and Gene Therapy (ASGCT) is a global society of opinion leaders and ...
By CellFE
-
Gyroscope Therapeutics Announces Research Collaboration Agreement with Children’s Medical Research Institute to Develop Novel Gene Therapy Capsids
Gyroscope Therapeutics Holdings plc (“Gyroscope”), a clinical-stage gene therapy company focused on treating diseases of the eye, today announced the company has entered a research collaboration with Children’s Medical Research Institute (“CMRI”) in Australia to develop next-generation clinical capsids, the protein shells of viral vectors used to deliver ...
-
Part of the Cell and Gene Therapy Catapult PAT Consortium
Imspex is delighted to be part of the ground-breaking process analytical technologies (PAT) consortium announced today by the Cell and Gene Therapy Catapult. The consortium of over 20 pharmaceutical companies, technology providers, therapy developers and charities is the largest in the cell and gene therapy space to date with a mission to co-create industry-specific solutions that improve ...
-
CellFE Biotech marks continued growth with new CBO hire
CellFE Biotech, a venture-backed startup focused on microfluidics-based platforms for cell and gene engineering, has announced the appointment of Kevin Gutshall as Chief Business Officer. Gutshall’s background in biotech-focused business development promises to bring a wealth of industry expertise to the CellFE executive team. Gutshall most recently served as the VP of Strategy and ...
By CellFE
-
Forge Biologics to Present at Morgan Stanley’s 20th Annual Global Healthcare Conference
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Christina Perry, Senior Vice President of Finance & Investor Relations, will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, in New York, NY. Concurrently, Forge will host one-on-one meetings with interested investors. Forge’s ...
-
Redbiotec Signs Collaboration Agreement with Large-Cap Pharma to Develop Targeted Living Medicines
Redbiotec AG has entered into a research collaboration and exclusive option agreement with a large-cap pharmaceutical company. The collaboration will leverage Redbiotec’s proprietary bacteria platform BRISPR® for the targeted delivery of gene therapy cargos from the partner. “Redbiotec’s bacteria hold great potential in overcoming the delivery hurdles faced by conventional ...
By Redbiotec AG
-
CellFE Biotech to Attend BIO Digital ‘21
CellFE Biotech, a gene therapy company focused on developing a microfluidics-based platform for cell engineering, will be attending the Bio Digital conference next week from June 14-18, 2021. While the conference will feature live and on-demand sessions, as well as presentations in the Innovation Stage, industry participants are able to use the events One-on-One Partnering feature for business ...
By CellFE
-
Planning for Commercial-Scale Production: Tools & Technologies of the Future
Following the publication of his article last year: How short-term gain can lead to long-term pain, we caught up with David James, CEO of Scinogy, to discuss whether the conversation has started to change within the industry as the sector looks to drive down costs and automate manufacturing of cell and gene therapies. ...
-
Holostem at the second asset talk organised by Clust-ER Health
On Thursday 3 June, the second event dedicated to the exploration of the assets identified during 2020 in the in-depth analysis of the potential and prospective attractiveness carried out on the health and wellness sector in Emilia-Romagna will be held. The theme of this meeting, which will start at 5 p.m., is advanced therapies: technically called ATMPs (Advanced Therapy Medicinal Products), ...
-
Virica Biotech to be Showcased in Xtalks Webinar: Process Intensification in AAV Gene Therapy
Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, will be featured in a live webinar to be held on Monday, November 14, 2022, at 2:30pm EST. This webinar will focus on process intensification in the manufacturing of adeno associated virus (AAV) vectors. AAV vectors are critical to gene therapy development. These vectors are the delivery ...
-
Halo Labs Launches The Aura Gt™ For Gene Therapy Product Quality – PR Newswire
Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest product, Aura GT. Aura GT is part of the next generation in Halo Labs’ popular family of instruments. Using Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy, Aura GT can distinguish aggregated capsids from contaminants, carrier ...
By Halo Labs
-
Forge Biologics to Present and Participate at Upcoming Investor Conferences
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that company leadership members will be making presentations and taking one-on-one meetings at three upcoming investor relations conferences. Jefferies Cell & Genetic Medicine Summit Friday, September 30, 10:00-10:25 a.m. ET Presenter: Christina Perry, Senior Vice President and Head, ...
-
Cell & Gene Therapy World 2018
Cytonome will be participating in the Phacilitate Cell and Gene Therapy World Conference in Miami from January 22nd-25th, 2018. Stop by the BioProcess Hub at Booth BPi to meet out team and learn about how the GigaSort Platform can deliver high throughput cell sorting in a manufacturing ...
-
CellFE platform enables microfluidic Transfection of mRNA into T cells and HSPCs
CellFE Biotech, a microfluidics-based biotech startup based out of Alameda, CA, has recently had an article published in Scientific Reports. The article, cited below, focuses on the use of a novel microfluidics platform to successfully achieve the transfection of mRNA into T-cells, particularly through volume exchange for convective transfection (VECT). The delivery of mRNA offers a distinct ...
By CellFE
-
Cell and Gene Therapy Industry Comes Together for Matica Bio’s New Global Event
Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, hosted an inaugural event this week, Global Cell & Gene Day, with CHA Medical & Bio Group, providing a specialized venue for learning, innovation and networking for the advancing cell and gene therapy ...
-
Comprehensive Gene Therapy Development Solutions to Further Boost Rare Disease Research
As several gene therapy approvals for rare disease treatment gain steam in 2023, a comprehensive set of gene therapy development solutions is released to pave richer avenues for rare disease research. This path-breaking move sees the integration of cutting-edge technology with state-of-art research facilities to amplify the possibilities of devising effective remedies for rare diseases. Rare ...
By Protheragen
-
Vybion Huntington`s Disease Drug Patent receives Track I Status
Vybion, Inc. is pleased to announce that its patent application covering methods of use and composition for INT41 Gene Therapy received Track I status from the USPTO. The INT41 patent application covers several neurodegenerative diseases in addition to Huntington's Disease including Spinal Cerebellar Ataxia, Spinal Muscular Atrophy, and Alzheimer's. "Vybion is pleased to receive Track I status on ...
By Vybion
-
Myrtelle and Forge Biologics Announce Viral Vector and Plasmid DNA cGMP Manufacturing Partnership
Myrtelle Inc., (Myrtelle), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced a manufacturing partnership that will advance Myrtelle’s novel gene therapy for monogenic hearing loss, Myr-201, into clinical trials ...
-
Gene therapy expert Dr. Michele Calos joins the Scientific Advisory Board of Redbiotec
Redbiotec AG, a pioneer in living medicines, further expands its Scientific Advisory Board with the appointment of Professor Michele Calos, PhD. Dr. Calos is a Professor of Genetics at Stanford University. A recent President of the American Society of Gene and Cell Therapy (ASGCT), Dr. Calos brings over four decades of research experience in genetics and genomic modification and has been ...
By Redbiotec AG
-
Virica Biotech Announces Collaboration with the Government of Canada to Make Gene Therapies More Accessible and Affordable for Canadians
Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, today announced it has received $400,000 from Innovation, Science and Economic Development Canada (ISED) through the Innovative Solutions Canada (ISC) program. This funding supports Virica’s collaboration with the National Research Council of Canada’s (NRC) Cell and Gene ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you